Vol.74 No.6 November 2026
A case of drug-induced liver injury caused by oral voriconazole in a patient with short bowel syndrome and 30 cm of residual small intestine
1)Department of Infectious Diseases, Okayama University Hospital, 2-5-1 Shikata, Kita-ku, Okayama, Japan
2)Department of General Medicine, Okayama University Hospital
3)Department of Bacteriology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine
4)Department of Pharmacy, Okayama University Hospital
5)Center of Infectious Disease Education, Kagawa University Hospital
6)Research Center for Intestinal Health Science, Okayama University
Abstract
A man in his sixties with short bowel syndrome (SBS), in whom a residual 30 cm of the small intestine from the Ligament of Treitz remained following bowel resection for non-occlusive mesenteric ischemia, was transferred to our hospital for management of refractory liver dysfunction. The patient had previously undergone ascending aorta–to–abdominal aorta bypass for aortitis syndrome. He was receiving treatment for persistent Candida parapsilosis candidemia with intravenous micafungin and voriconazole (VRCZ), when he developed laboratory evidence of liver injury. Intravenous VRCZ was switched to oral therapy despite concerns about limited drug absorption. However, in fact, the serum concentrations rose significantly, leading to worsening the VRCZ-induced liver injury. Following dose reduction guided by therapeutic drug monitoring (TDM), the blood cultures turned positive once the serum levels fell within the standard therapeutic range, rendering VRCZ clinically non-viable. This case serves to highlight the fact that even with an extremely short remnant intestine of 30 cm, a sufficient amount of VRCZ can be absorbed into the blood, possibly owing to intestinal adaptation, further highlighting the risk of an unexpectedly high concentration caused by individual differences in metabolic capacity and drug interactions.
Key word
voriconazole, short bowel syndrome, hepatotoxicity, therapeutic drug monitoring
Received
March 3, 2026
Accepted
July 9, 2026
Jpn. J. Chemother. 74 (6): 785-791, 2026


